article Open AccessTop 1% cited
Acid‐inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects ‐ a randomised open‐label cross‐over study
Alimentary Pharmacology & Therapeutics · 2015 · Vol. 42(6) · pp. 719–730
Yuichi Sakurai✉(Takeda (Japan))Yujiro Mori(Takeda (Japan))Hiroyuki Okamoto(Takeda (Japan))Akira Nishimura(Takeda (Japan))Emiko Komura(Takeda (Japan))Tsuyoshi Araki(Takeda (Japan))Masanari Shiramoto
Abstract
This study demonstrated a more rapid and sustained acid-inhibitory effect of vonoprazan 20 mg vs. esomeprazole 20 mg or rabeprazole 10 mg. Therefore, vonoprazan may be a potentially new treatment for acid-related diseases.
Gastroesophageal reflux and treatmentsHelicobacter pylori-related gastroenterology studiesAsthma and respiratory diseasesRabeprazoleEsomeprazoleMedicineOpen labelInternal medicineGastroenterologyPharmacologyRandomized controlled trialProton-pump inhibitor
MeSH terms
AdultGastric AcidHumansHydrogen-Ion ConcentrationMaleMiddle AgedPyrrolesResearch DesignSulfonamidesCross-Over StudiesProton Pump InhibitorsEsomeprazoleRabeprazole
Funding
- Takeda Pharmaceutical Company
Citations
372
FWCI
22.37
field-weighted impact
References
26
Percentile
100%
vs. same field & year
Citations per year
References
Systematic review: proton‐pump inhibitor failure in gastro‐oesophageal reflux disease – where next?
Alimentary Pharmacology & Therapeutics · 2005 · 392 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.